Vesugen

Vesugen (Lys-Glu-Asp; KED) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson as part of a decades-long program investigating short-chain peptide regulation of age-associated tissue decline. The compound belongs to the Khavinson class of ultrashort (two to four amino acid residue) bioregulatory peptides, a family of synthetic sequences derived from organ-specific protein fractions that are proposed to penetrate cell nuclei and modulate gene expression through direct interactions with DNA promoter regions and epigenetic regulatory mechanisms. Vesugen is the synthetic analog corresponding to the vascular-wall-derived peptide fraction originally isolated as the active component of Ventfort, a polypeptide complex extracted from bovine aortic tissue. The tripeptide sequence Lys-Glu-Asp was identified as the minimal bioactive motif responsible for the vasoprotective activity of the parent extract.

The molecular pharmacology of Vesugen is characterized by epigenetic modulation of vascular endothelial cell function. In dissociated human endothelial cell cultures, Vesugen stimulates synthesis of the proliferation-associated protein Ki-67, the expression of which declines during cellular aging [1]. Molecular docking studies demonstrate that Vesugen binds to the promoter region of the MKI67 gene, making contact through the CATC sequence at the core promoter located between positions -14 and +12 relative to the transcription initiation site [1]. In models of atherosclerotic and restenotic endothelium in vitro, Vesugen normalizes the expression of endothelin-1, restores connexin (Cx37, Cx43) expression for intercellular communication, and increases sirtuin-1 (SIRT1) expression, implicating the compound in DNA repair and cellular longevity pathways [2, 3]. The compound also modulates expression of vascular endothelial growth factor (VEGF) and the apoptosis marker p53, contributing to a net pro-proliferative and anti-apoptotic phenotype in aged vascular endothelial cells.

Beyond its primary vascular target, Vesugen has demonstrated neuroprotective activity in several preclinical models. The tripeptide regulates expression of cell aging and apoptosis genes (p16, p21), neuronal differentiation genes and proteins (NES, GAP43, nestin), and genes implicated in Alzheimer's disease pathogenesis (SUMO, APOE, IGF1) [4]. In hippocampal neuron cultures exposed to amyloid-beta synaptotoxicity, Vesugen increased the number of mushroom-type dendritic spines by 20 percent [5]. Oral administration of Vesugen improved memory and attention in elderly individuals with functional central nervous system disorders in a small clinical cohort [4]. In a 32-patient clinical study of elderly individuals with chronic polymorbidity and organic brain syndrome, Vesugen demonstrated anabolic properties and improved central nervous system activity, slowing the rate of aging as measured by biological age indicators [6].

The compound is not approved by any national regulatory authority as a pharmaceutical product. It is supplied as a research-grade synthetic peptide and as a dietary supplement (capsule form) in certain jurisdictions. The primary literature on Vesugen originates predominantly from Russian research institutions, principally the Saint Petersburg Institute of Bioregulation and Gerontology and affiliated laboratories. Independent replication by Western laboratories using contemporary structural biology and pharmacology methodologies remains limited. This monograph reviews the chemistry, proposed mechanism of action, preclinical pharmacology, limited clinical evidence, sourcing and handling considerations, and a comparative assessment against five alternative vasoprotective and geroprotective peptide candidates.